Epalrestat Combined With HAIC, Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable HCC and Diabetes
A Multicenter, Prospective, Single-arm Clinical Study Evaluating the Efficacy and Safety of Epalrestat Combined With Hepatic Arterial Chemotherapy Infusion (HAIC), Donafenib and Tislelizumab as First-line Treatment for Patients With Unresectable Hepatocellular Carcinoma and Diabetes
The purpose of this study is to evaluate the comprehensive therapeutic efficacy and safety profile of the epalrestat combined with hepatic artery infusion chemotherapy (HAIC), donafenib and tislelizumab quadruple regimen in patients with unresectable hepatocellular carcinoma (HCC) and diabetes.
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Hongbin Zou
- 電話番号:+8618040026871
- メール:hongbinzou300@gmail.com
研究場所
-
-
Heilongjiang
-
Harbin、Heilongjiang、中国、150085
- まだ募集していません
- Harbin Medical University Cancer Hospital
-
コンタクト:
- Dongfeng He
- 電話番号:18040026871
- メール:2919534184@qq.com
-
-
Jilin
-
Yanji、Jilin、中国、133000
- 募集
- Yanbian University Hospital
-
コンタクト:
- Songnan Zhang
- 電話番号:18040026871
- メール:2919534184@qq.com
-
-
Liaoning
-
Shenyang、Liaoning、中国、110000
- 積極的、募集していない
- The First Hospital of China Medical University
-
Shenyang、Liaoning、中国、110001
- まだ募集していません
- Liaoning Cancer Hospital
-
コンタクト:
- Wenheng Zheng
- 電話番号:18040026871
- メール:2919534184@qq.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diabetes mellitus combined with unresectable advanced HCC (BCLC stage C);
- Patients who have the need for treatment, prevention and improvement of diabetic neuropathy;
- Liver function at Child-Pugh grade A or B (≤ 7 points), ECOG PS 0-1;
- Age 18-80 years old. Confirmed as unrectable HCC through pathological or imaging diagnosis;
Exclusion Criteria:
- Severe liver dysfunction: Child-Pugh C grade (≥ 8 points) or active hepatic encephalopathy Illness;
- Extensive extrahepatic metastases (e.g., lung, bone, or peritoneum metastases);
- Severe cardiovascular diseases: Uncontrolled heart failure, recent myocardial infarction;
- Renal failure: Creatinine clearance rate < 30 mL/min;
- Thrombocytopenia (less than 50×10⁹/L) or coagulation dysfunction (INR greater than 1.5);
- Active infection (such as uncontrolled hepatitis B virus replication with HBV-DNA > 2000 IU/mL);
- ECOG PS ≥ 2 or extremely poor overall condition;
- Diabetic patients with acute ketoacidosis or during the period of severe infection;
- Pregnant and lactating women;
- Known history of other malignancy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Epalrestat plus HAIC, donafenib and tislelizumab
Epalrestat 50mg tid, donafenib 0.2g bid, tislelizumab 200mg per 21days, HAIC (FOLFOX or RALOX) per 21days |
For the first 6 patients in the safety lead-in period, the starting dose of epalrestat was 50 mg, three times per day. If dose-limiting toxicity (DLT) occurred in the first 6 patients, the dose for the second round of 6 patients in the safety lead-in period would be adjusted to 50 mg, twice per day. If DLT occurred in the second round of 6 patients, the dose for the third round of 6 patients in the safety lead-in period would be adjusted to 50 mg, once per day. donafenib 0.2g BID, tislelizumab 200mg/21days Include FOLFOX and RALOX.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
12-month Event-free survival (EFS) Rate
時間枠:From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
The proportion of patients who have remained event-free from the start of treatment until the 12-month time point.(Predefined events include: progression of disease, death for any reason, terminate the treatment due to intolerable AEs.) |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Event-free survival (EFS)
時間枠:From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
Defined as the time from treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs). |
From treatment to the first occurrence of a predefined event (progression of disease, death for any reason, terminate the treatment due to intolerable AEs), assessed up to 2 years.
|
|
Overall survival (OS)
時間枠:Up to approximately 2 years
|
The OS is defined as the time from the enrollment to death due to any cause. |
Up to approximately 2 years
|
|
Progression free survival(PFS) (Overall)
時間枠:From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease (according to mRECIST) or death due to any cause, whichever occurs first. |
From enrollment to progressive disease (according to mRECIST) or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of intra-hepatic lesions
時間枠:From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented progressive disease of intra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Progression free survival(PFS) of extra-hepatic lesions
時間枠:From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
The PFS is defined as the time from the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, whichever occurs first. |
From the enrollment to the first documented appearance of extra-hepatic lesions or death due to any cause, up to 2 years.
|
|
Objective response rate(ORR) per RESCIST 1.1
時間枠:Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented complete response(CR) or partial response(PR) per RECIST 1.1. |
Up to approximately 2 years
|
|
ORR per mRECIST
時間枠:Up to approximately 2 years
|
The ORR is defined as the proportion of patients with a documented CR or PR per mRECIST. |
Up to approximately 2 years
|
|
PVTT response rate per mRECIST
時間枠:Up to approximately 2 years
|
The PVTT response rate is defined as the proportion of patients with a documented CR or PR of PVTT. According to the Vp classification: CR: PVTT disappears or the portal vein becomes completely unobstructed. PR: Decrease in VP classification. SD: Without PR and PD. PD: Increase in VP classification. |
Up to approximately 2 years
|
|
Disease control rate(DCR) per RESCIST 1.1
時間枠:Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per RECIST 1.1. |
Up to approximately 2 years
|
|
DCR per mRECIST
時間枠:Up to approximately 2 years
|
The DCR is defined as the proportion of patients with a documented complete response(CR), partial response(PR) or stable disease(SD) per mRECIST. |
Up to approximately 2 years
|
|
Adverse event(AE) per Common Terminology Criteria for Adverse Events(CTCAE) 5.0
時間枠:Up to approximately 2 years
|
The percentage and degree of patients who experience at least one AE, whether or not considered related to the treatment, according to CTCAE version 5.0. |
Up to approximately 2 years
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Haibo Shao、First Hospital of China Medical University
- 主任研究者:Tao Han、First Hospital of China Medical University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- kelunshen【2025】2025-861-2
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Consent and privacy: Participants usually only agreed to data use in the original study. Sharing IPD may violate that agreement. And we want to protect our academic credit and avoid misuse of the data.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。